Form D · Biotechnology
NanoView Biosciences, Inc.
Boston, MA · CIK 0001754605
Offering snapshot reported Mar 1, 2022 · SEC filing
- Reported sold
- $2.5M Offering amount: $5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2022 | Initial | $2,500,000 | No comparison | 2 | SEC filing |
| Dec 2, 2020 | Initial | $6,000,000 | No comparison | 4 | SEC filing |
| Oct 3, 2018 | Initial | $9,000,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-435377
Source: Form D, filed Mar 1, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Parker Cassidy | Director |
| George Daaboul | Director |
| David Freedman | Executive |
| Andrea Jackson | Director |
| Ian Ratcliffe | Director |
| Michael Rubin | Director |
| Gerald Williamson | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1380 Soldiers Field Road Suite 100
Boston, MA, 02135
Boston, MA, 02135